| Ytd | -23.25% | |
| 1y | 46.80% |
| Open | 5.02 | Prev Close | 4.99 | Low | 4.88 | High | 5.17 | Mkt Cap | 326.72M |
| Vol | 1.07M | Avg Vol | 1.50M | EPS | -1.06 | P/E | N/A | Forward P/E | -1.34 |
| Beta | -0.40 | Short Ratio | 1.19 | Inst. Own | 30.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 4.94 | 200-d Avg | 5.71 | 1yr Est | 12.42 |
IMRX News
Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping can
Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping can
- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months fo
US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumpe
Zoom Communications Inc shares rise after strong financial results and increased buyback authorizat
Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping can
Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.21) per share which beat the analyst cons
- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic canc
Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping can
Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.18) per share which beat the analyst cons
Benzinga examined the prospects for many investors' favorite stocks over the last week — here
Immuneering shares traded lower after new pancreatic cancer trial data showed improved survival, man
(Editor’s note: The future prices of benchmark tracking ETFs and the headline were updated in the st
Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping can
Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping ca
– End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA –– Company expe
Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping can
Chardan Capital analyst Geulah Livshits maintains Immuneering (NASDAQ:IMRX) with a Buy and mainta
Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.38) per share which beat the analyst cons
Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session.
Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced
A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some
Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 200 points
Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported fi
U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points on
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tues